Simon, Florian, Giza, Adam, Robrecht, Sandra, Fink, Anna-Maria, Cramer, Paula ORCID: 0000-0003-4046-9922, von Tresckow, Julia, Fuerstenau, Moritz, Goede, Valentin, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael ORCID: 0000-0002-7425-4455 and Al-Sawaf, Othman (2022). Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older. Leuk. Lymphoma, 63 (14). S. 3299 - 3307. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Full text not available from this repository.

Abstract

Patients aged 80 years and older make up a fifth of patients with CLL but are underrepresented in clinical trials. We analyzed the outcomes of these patients treated with targeted agents in the front-line setting in six trials of the German CLL Study Group. Targeted agents included venetoclax, ibrutinib, and idelalisib, mainly used in combination with anti-CD20 antibodies. Among 716 patients, 33 matched the selection criteria (5%). Of those, the majority had relevant comorbidity, organ dysfunctions, and/or high-/very high-risk disease. The overall response rate was 73%. The median progression-free survival was 49.2 months compared with those not reached in younger patients. There were 11 documented deaths of which two were deemed related to therapy. Additional results including 40 patients treated with BTK-inhibitors from the GCLLSG registry suggest that treatment with targeted agents is feasible and effective. Dedicated studies are warranted for this particular subgroup of patients.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Simon, FlorianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Giza, AdamUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Robrecht, SandraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fink, Anna-MariaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cramer, PaulaUNSPECIFIEDorcid.org/0000-0003-4046-9922UNSPECIFIED
von Tresckow, JuliaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fuerstenau, MoritzUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goede, ValentinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tausch, EugenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schneider, ChristofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stilgenbauer, StephanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wendtner, Clemens-MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eichhorst, BarbaraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fischer, KirstenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hallek, MichaelUNSPECIFIEDorcid.org/0000-0002-7425-4455UNSPECIFIED
Al-Sawaf, OthmanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-688291
DOI: 10.1080/10428194.2022.2123223
Journal or Publication Title: Leuk. Lymphoma
Volume: 63
Number: 14
Page Range: S. 3299 - 3307
Date: 2022
Publisher: TAYLOR & FRANCIS LTD
Place of Publication: ABINGDON
ISSN: 1029-2403
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
INTERNATIONAL SOCIETY; GERIATRIC ASSESSMENT; ELDERLY-PATIENTS; IBRUTINIB; CLL; VENETOCLAX; OBINUTUZUMAB; MANAGEMENT; SURVIVAL; TRIALMultiple languages
Oncology; HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/68829

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item